Carfilzomib Improves Bone Metabolism in Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results of the CarMMa Study

SIMPLE SUMMARY: Carfilzomib with dexamethasone is an important therapeutic option for patients with relapsed/refractory multiple myeloma. We sought to evaluate the effect of this regimen on the bone-related outcomes, which are associated with both quality of life and survival. Among 25 patients, les...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancers (Basel)
Auteurs principaux: Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Katodritou, Eirini, Kyrtsonis, Marie-Christine, Douka, Vassiliki, Spanoudakis, Emmanouil, Papatheodorou, Athanasios, Eleutherakis-Papaiakovou, Evangelos, Kanellias, Nikolaos, Gavriatopoulou, Maria, Makras, Polyzois, Kastritis, Efstathios, Dimopoulos, Meletios A
Format: Artigo
Langue:Inglês
Publié: MDPI 2021
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7998249/
https://ncbi.nlm.nih.gov/pubmed/33809268
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13061257
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires